

Examiner-Initiated Interview Summary	Application No. 10/070,439	Applicant(s) MURAKAMI ET AL.
	Examiner Thomas McKenzie Ph.D.	Art Unit 1624

All Participants:**Status of Application:** _____(1) Thomas McKenzie Ph.D.

(3) _____

(2) Daniel J. Pereira, Ph.D.

(4) _____

Date of Interview: 26 February 2004**Time:** 3:45**Type of Interview:** Telephonic Video Conference Personal (Copy given to: Applicant Applicant's representative)Exhibit Shown or Demonstrated: Yes No

If Yes, provide a brief description:

Part I.

Rejection(s) discussed:

enablement for treating obesity and ketoacidosis

Claims discussed:

15 and 24

Prior art documents discussed:


*Yamauchi (J. Clin. Invest.) and Yamauchi (J. Biol. Chem.)***Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
- It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.



(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: while the new general use claims would be allowable, the two specific disease treatment claims would lack enablement. Neither document cited by Applicants provides any clinical data would be required to provide the correlation between Applicants' assay and their proposed disease treatments. Such treatment is still speculative.